Abstract:The essential trace element iron is a key component of hemoglobin, playing a role in erythropoiesis and oxygen transport. In addition, iron plays a key role in several enzymatic and metabolic processes. Iron deficiency causes anemia, whereas iron overload causes organ-related diseases such as heart failure, liver cirrhosis, and diabetes mellitus. Therefore, maintaining iron homeostasis is essential for the survival of nearly all living organisms. Iron overload-related cardiomyopathy is a secondary form of heart disease resulting from iron accumulation in the myocardium and is the leading cause of morbidity in hereditary hemochromatosis, thalassemia major, and other conditions associated with secondary iron overload. A growing body of epidemiological and molecular evidence supports the notion that iron overload is pathogenic and that iron chelation therapy can be clinically beneficial in treating many forms of heart disease. However, the precise mechanisms by which iron overload leads to heart disease are poorly understood. In recent years, significant progress has been made toward understanding the regulatory mechanisms that underlie iron overload in many diseases. In particular, ferroptosis, a newly identified iron-dependent form of cell death, has drawn considerable attention. Ferroptosis has morphological, biochemical, and genetic features that are distinct from other forms of cell death such as apoptosis, necrosis, and autophagy, and mounting evidence suggests that ferroptosis participates in the initiation and progression of many diseases and conditions, including tumorigenesis, ischemia/reperfusion injury, kidney failure, and diseases affecting the nervous system and the hematological system. Although the death of terminally differentiated cardiomyocytes is a crucial pathogenic factor in the development of cardiomyopathy, the underlying mechanism remains unknown. Recently, we reported that inhibiting ferroptosis in mice can protect against both chemotherapy-induced cardiomyopathy and ischemia/reperfusion-induced cardiomyopathy. With respect to the underlying mechanism, we found that excess accumulation of free iron in the mitochondria of cardiomyocytes causes membrane lipid peroxidation, providing new insights into the pathogenic mechanisms that underlie iron overload-associated cardiomyopathy. In this review, we briefly introduce the molecular mechanisms that regulate cardiac iron homeostasis. In addition, we provide an overview of studies regarding the role that iron overload-associated cardiomyopathy and ferroptosis play in the pathogenesis and progression of heart disease. Finally, we discuss the role of targeting ferroptosis as a promising new therapeutic strategy for myocardial chemotherapeutic and ischemia/reperfusion injury.

Macrophage-derived extracellular vesicles represent a promising endogenous iron-chelating therapy for iron overload and cardiac injury in myocardial infarction

Nanosponge for Iron Chelation and Efflux: A Ferroptosis‐Inhibiting Approach for Myocardial Infarction Therapy

Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases

Melanin Nanoparticles As an Endogenous Agent for Efficient Iron Overload Therapy

Exogeneous Metal Ions As Therapeutic Agents in Cardiovascular Disease and Their Delivery Strategies.

Multifaceted Role of Ferroptosis in Cardiovascular Disease

Pre-emptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction

Ferroptosis: a new strategy for cardiovascular disease

Ferroptosis as a novel therapeutic target for cardiovascular disease

Role of Iron Overload and Ferroptosis in Heart Disease

Herbal medicines provide regulation against iron overload in cardiovascular diseases: Informing future applications

Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency

Targeting ferroptosis: a novel insight against myocardial infarction and ischemia-reperfusion injuries

Effects of 2,3-dimercaptosuccinic acid modified Fe2O3 nanoparticles on microstructure and biological activity of cardiomyocytes

Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications

Persistent Ferroptosis Modulates Cardiac Remodeling and M2 Macrophage Polarization, Which Can be Mitigated by Astaxanthin During Myocardial Infarction Recovery

Targeting ferroptosis and ferritinophagy: new targets for cardiovascular diseases

Ferroptosis: The Potential Target in Heart Failure with Preserved Ejection Fraction

Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure

The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease

Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy